Braintree Hits Amrutham With Laxative Patent Suit

Law360, New York (March 17, 2011, 12:47 PM EDT) -- Braintree Laboratories Inc. filed an infringement action in Pennsylvania on Wednesday to block Amrutham Inc. from marketing a generic version of the laxative drug Suprep, days after pouncing on Novel Laboratories Inc.'s own effort to introduce a bowel-cleansing drug.

The complaint, lodged in the U.S. District Court for the Eastern District of Pennsylvania, alleges that Amrutham’s abbreviated new drug application at the U.S. Food and Drug Administration for a sodium sulfate, potassium sulfate and magnesium sulfate bowel cleanser infringes the Suprep patent.

The proposed drug has...
To view the full article, register now.